Patents Examined by Gregory S. Emch
  • Alzheimer's disease assay in a living patient
    Patent number: 9354223
    Abstract: An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of ?7nAChR or TLR4 in a FLNA-captured protein complex or ?7nAChR in an A?-captured protein complex or ?7nAChR-FLNA, or TLR4-FLNA and/or ?7nAChR-A?42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of medicament that is less than the first amount indicates a favorable treatment prognosis.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: May 31, 2016
    Assignee: Pain Therapeutics Inc.
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Immunization with amyloid-beta oligomers
    Patent number: 9340606
    Abstract: The present invention provides methods of immunization against Alzheimer's Disease and compositions for use in such methods.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: May 17, 2016
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Michael Sierks, Srinath Kasturirangan
  • HSP20 inhibits amyloidogenesis and neurotoxicity
    Patent number: 9321817
    Abstract: The present inventions are compositions and methods of using at least a portion of an isolated and purified ?-crystallin polypeptide that includes one or more ?-pleated sheets and that prevents neurotoxicity and amyloidogenesis.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: April 26, 2016
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Allison Ficht, Theresa Good, Kenneth Carson, Sungmun Lee
  • Use of an anti-Tau pS422 antibody for the treatment of brain diseases
    Patent number: 9290567
    Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: March 22, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Ulrich Goepfert, Fiona Grueninger, Walter Huber, Hans-Willi Krell, Valeria Lifke, Olaf Mundigl, Sonja Offner, Laurence Ozmen, Michael Schraemi
  • AGER-peptides and use thereof
    Patent number: 9291621
    Abstract: The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor multimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER.
    Type: Grant
    Filed: January 18, 2006
    Date of Patent: March 22, 2016
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Alfred Hahn, Ralf Loebbert, Nicole Teusch, Achim Möller, Ulrich Ebert, Martin Schmidt
  • Method for achieving desired glial growth factor 2 plasma levels
    Patent number: 9272015
    Abstract: The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: March 1, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Haesun Kim, Anthony O. Caggiano
  • Use of tau to monitor immunotherapy
    Patent number: 9272030
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: March 1, 2016
    Assignees: JANSSEN SCIENCES IRELAND UC, WYETH LLC
    Inventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini, Gene G. Kinney
  • Methods for altering mRNA splicing and treating familial dysautonomia by administering benzyladenine
    Patent number: 9265766
    Abstract: This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding to the mutant protein or ii) a component in the splicing machinery responsible for processing the misspliced mRNA. In addition, this invention relates to treating individuals having a disorder associated with a misspliced mRNA, such as Familial Dysautonomia or Neurofibromatosis 1, by administering to such an individual a cytokinin such as kinetin.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: February 23, 2016
    Assignee: The General Hospital Corporation
    Inventors: Susan A. Slaugenhaupt, James F. Gusella
  • Vectors encoding rod-derived cone viability factor
    Patent number: 9265813
    Abstract: The present invention relates to nucleic acids coding for and capable of expressing a rod-derived cone viability factor (RdCVF) and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting an RdCVF, and methods of treatment.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 23, 2016
    Assignee: Wellstat Ophthalmics Corporation
    Inventor: Tianci Luo
  • Conformational-switching fluorescent protein probe for detection of alpha synuclein oligomers
    Patent number: 9261514
    Abstract: A conformation-switching fluorescent protein probe for detection of alpha synuclein oligomers using an alpha synuclein (?S) variant, PG65 (SEQ ID NO: 4), together with a conformation-sensitive fluorescent molecule to create a molecular probe for rapid, specific, and quantitative detection of ?S oligomers.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: February 16, 2016
    Assignee: New York University
    Inventors: Jin Ryoun Kim, Michael Hernandez
  • Antibody, kit and method for determining amyloid peptides
    Patent number: 9255932
    Abstract: The invention relates to the field of immunoassays which allow the detection of A?17 peptides by virtue of the use of an anti-A?17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: February 9, 2016
    Assignee: Aracion Biotech, S.L.
    Inventor: Manuel Sarasa Barrio
  • Compositions for treatment of neurodegenerative diseases
    Patent number: 9243032
    Abstract: Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: January 26, 2016
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Ronit Shaltiel-Karyo, Ehud Gazit
  • Therapy for subarachnoid hemorrhage and ischemia
    Patent number: 9241970
    Abstract: The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefiting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: January 26, 2016
    Assignee: NoNO Inc.
    Inventor: Michael Tymianski
  • Botulinum toxin treatment of anxiety and bipolar disorders
    Patent number: 9238061
    Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: January 19, 2016
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Amyloid protein oligomer-binding aptamer
    Patent number: 9238816
    Abstract: An aptamer having a G-quartet structure and being at least one selected from the group consisting of the following polynucleotides, the aptamer having a binding ability to an amyloid protein oligomer: (1) a polynucleotide comprising a base sequence represented by any one of SEQ ID NO:1 to SEQ ID NO:18; (2) a polynucleotide comprising a base sequence that includes at least four sets of at least two consecutive guanosine nucleotides and in which one or several bases has been deleted, substituted, or added in a base sequence represented by any one of SEQ ID NO:18; and (3) a polynucleotide that is a multimer including the polynucleotide of (1) or (2) as a structural unit.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: January 19, 2016
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY
    Inventors: Kazunori Ikebukuro, Kaori Tsukakoshi, Koji Sode
  • Engineered zinc finger proteins for treating trinucleotide repeat disorders
    Patent number: 9234016
    Abstract: Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: January 12, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Philip D. Gregory, Edward J. Rebar, H. Steve Zhang
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 9234031
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 12, 2016
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Anti-sAPP? antibody
    Patent number: 9222947
    Abstract: Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP ? or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPP? contained in a biological sample.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: December 29, 2015
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tatsuya Takahashi, Junji Onoda, Yasunobu Yoshida, Shoji Yamane, Kouhei Nishitomi, Hidekuni Yamakawa, Akira Yamauchi, Atsushi Morita, Isao Fukuda
  • Oligomer-specific amyloid beta epitope and antibodies
    Patent number: 9216217
    Abstract: A novel constrained peptide epitope derived from A?, wherein the eptitope comprises the amino acid sequence SNK, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope which comprises the amino acid sequence SNK and corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A? is described. An antigenic peptide comprising an epitope having a constrained cyclic configuration, which comprises the amino acid sequence SNK and corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A? is also described. Methods of treating, preventing and diagnosing Alzheimer's disease are also described.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: December 22, 2015
    Assignee: The University of British Columbia
    Inventor: Neil R. Cashman
  • Treatment of amyloidoses using myelin basic protein and fragments thereof
    Patent number: 9217013
    Abstract: In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibrillization of peptides implicated in the amyloidoses, especially the amyloid-b eta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: December 22, 2015
    Assignee: The Research Foundation For the State University of New York
    Inventor: William E. van Nostrand